Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Aufreinigung
SHOC2 Antibody is affinity chromatography purified via peptide column.
Immunogen
SHOC2 antibody was raised against a 21 amino acid synthetic peptide near the amino terminus of human SHOC2. The immunogen is located within amino acids 30 - 80 of SHOC2.
SHOC2
Reaktivität: Human
WB, IHC (p)
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
SHOC2 antibody can be used for detection of Shoc2 by Western blot at 1-2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
SHOC2 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
SHOC2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
SHoc2/Sur8 (SHOC2)
(Leucine-rich repeat protein SHOC-2 (SHOC2))
SHOC2 Antibody: SHOC2 protein participates in protein binding / transferase activity in the fibroblast growth factor receptor signaling pathway and Ras protein signal transduction. It is a widely expressed protein composed almost entirely of leucine-rich repeats (LRR), with a lysine-rich sequence at the amino terminus and cytoplasmically localized. SHOC2 acts as a positive modulator of the RAS-MAPK signaling cascade, which is elicited by EGL-15 and LET-23 and mediated by LET-60. SHOC2 together with protein phosphatase 1c (PP1c) forms a highly specific M-Ras effector complex and is essential for activation of the MAPK pathway by growth factors. Furthermore, in tumor cells with Ras gene mutations, inhibition of SHOC2 expression inhibits MAPK, but not PI3K activity. The SHOC2-PP1c holoenzyme provides an attractive therapeutic target for inhibition of the MAPK pathway in cancer. Recent studies show that aberrantly acquired N-myristoylation of SHOC2 causes human disease Noonan-like syndrome with loose anagen hair.